Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-masked, Sham-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) - GLOW2

Next Previous
Trial Profile

A Prospective, Randomized, Double-masked, Sham-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) - GLOW2

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tarcocimab tedromer (Primary)
  • Indications Diabetic retinopathy; Retinal vein occlusion; Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms GLOW2
  • Sponsors Kodiak Sciences

Most Recent Events

  • 14 May 2025 According to Kodiak Sciences media release, the company plans to host an Investor R&D Update on July 16, 2025 at 1:00pm ET. The update will feature expected timeline to topline data.
  • 10 Mar 2025 According to Kodiak Sciences media release, Dr. Allen Hu is a principal investigator of this study.
  • 10 Mar 2025 According to Kodiak Sciences media release,all patients are expected to complete their primary endpoint visits by the end of January 2026. Also, the company expect to announce topline clinical data in 1Q 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top